Related Experiment Video
Updated: Jul 16, 2026

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
Published on: November 3, 2010
Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?
Y Jounaïdi1, V Hyrailles, L Gervot
1INSERM U CNRS, Montpellier, France.
Abstract:
In liver samples from 19 Caucasian subjects, the CYP3A5 protein was detected in 74% of individuals (14/19), while the messenger was shown to be expressed in 100% of individuals, assessed by the RT-PCR method. In order to characterise the putative mutation(s) in the messenger, accounting for the absence of protein accumulation, the full coding region of the CYP3A5 cDNA was sequenced for two unrelated individuals, one expressing the protein at a high level and one being defective. A point mutation in exon 11 at position 1280 (C-->A) was found to cosegregate with the absence of protein accumulation in 2 of the 5 defective individuals. This mutation produces a change in the amino acid at position 398 (Thr-->Asn). Whether this mutation affects the stability of the protein or whether it is in linkage desequilibrium with other mutation(s) in the non-coding region of the messenger is not known. The C-->A change at 1280 generates a Tsp509 I site which can be used for routine evaluation of the frequency of this mutation in population studies.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

